-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The European Commission has approved Sanofi and the biopharmaceutical Dupixent, which allows it to be used to treat endexual dermatitis in children between the ages of 6 and 11.
the approval was based on data from dupilumab's key Phase III efficacy and safety studies of dupilumab combined local corticosteroids (TCS), the average improvement rate for patients in the Dupixent group was 82 percent, compared with 49 percent for patients who used TCS alone.
were given Dupixent every two weeks, participants showed significant improvements in the degree and severity of the disease.
in addition, 33 percent and 39 percent of patients in the placebo group had transparent or almost transparent skin when using Dupilumab and TCS every four and two weeks, respectively, while the placebo group had 11 percent and 10 percent, respectively.
was used every four weeks and two weeks, the biotherapy also reduced itching by 51 percent and 61 percent, compared with 12 percent and 13 percent for placebos.
The Dupixent is a novel treatment that has been used by thousands of patients around the world, including patients with epigenetic dermatitis and other inflammatory diseases, such as chronic sinusitis," said George Yancopoulos, chief scientific officer of
Regeneron.
。
